Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
KLISYRI (tirbanibulin) ointment is a microtubule inhibitor for topical use. The chemical name of tirbanibulin is N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin-2-yl) acetamide. The molecular weight is 431.4 and the molecular formula is C26H29N3O3. Tirbanibulin’s structural formula is:
 |
Tirbanibulin ointment 1% contains 10 mg tirbanibulin per gram of white to off-white ointment containing mono- and di-glycerides and propylene glycol.
KLISYRI is indicated for the topical field treatment of actinic keratosis on the face or scalp.
For topical use only; not for oral or ophthalmic use.
Apply KLISYRI evenly to cover up to 100 cm² treatment field on the face or balding scalp once daily for 5 consecutive days using 1 unit-dose packet per application.
Wash hands immediately with soap and water after application.
Avoid washing and touching the treated area for approximately 8 hours after application of KLISYRI. Following this time, the area may be washed with a mild soap.
Avoid transfer of KLISYRI to the periocular area [see WARNINGS AND PRECAUTIONS].
Avoid application near and around the mouth and lips.
Ointment: 1% white to off-white ointment supplied in a unit-dose packet (2.5 mg tirbanibulin in 250 mg or 3.5 mg tirbanibulin in 350 mg).
KLISYRI is a white to off-white ointment and is supplied in unit-dose packets containing either 250 mg or 350 mg of tirbanibulin ointment 1%. Discard each unit-dose packet after use.
NDC 16110-391-05 (5 unit-dose packets each containing 250 mg of ointment)
NDC 16110-391-55 (5 unit-dose packets each containing 350 mg of ointment)
Store at 20°C-25°C (68°F-77°F), excursions permitted to 15°C-30°C (59°F-86°F) [see USP Controlled Room Temperature]. Do not refrigerate or freeze.
Manufactured for: Almirall, LLC, Malvern, PA 19355 USA. Revised: Jun 2024
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Two double-blind, vehicle-controlled clinical trials were conducted in 702 adult subjects with actinic keratosis on the face or scalp. Subjects were randomized 1:1 to KLISYRI or vehicle. Subjects enrolled in the trials had 4 to 8 clinically typical, visible, and discrete AK lesions in a contiguous area of 25 cm² on the face or scalp. Subjects’ average age was 70 years (range 45 to 96 years) and they were predominantly White (99%), male (87%), with Fitzpatrick skin types I or II (72%) and actinic keratosis on the face (68%) or scalp (32%). Treatment groups were comparable across all demographics and baseline characteristics, including AK lesion count and distribution on the face or scalp.
In the controlled trials, local skin reactions (LSRs) were collected independent of adverse events. Local skin reactions including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, erosions/ulcerations were assessed by the investigators using a grading scale of 0 = absent, 1 = mild (slightly, barely perceptible), 2 = moderate (distinct presence), and 3 = severe (marked, intense).
The percentages of subjects with the maximal post-baseline grades for each local skin reaction (LSR) greater than baseline by treatment group are provided in Table 1. LSRs were mostly mild to moderate in severity (Table 1).
Table 1 : Post-Baseline Local Skin Reactions in the Treatment Area (face or scalp) - Pooled Data from 2 Controlled Clinical Phase 3 Trials
| Local Skin Reactions | KLISYRI N = 353 |
Vehicle N = 349 |
||||
| Mild n (%) |
Moderate n (%) |
Severe n (%) |
Mild n (%) |
Moderate n (%) |
Severe n (%) |
|
| Erythema | 76 (22%) | 223 (63%) | 22 (6%) | 98 (28%) | 20 (6%) | 0 |
| Flaking/ Scaling | 92 (26%) | 166 (47%) | 31 (9%) | 86 (25%) | 33 (9%) | 1 (<1%) |
| Crusting | 107 (30%) | 50 (14%) | 7 (2%) | 31 (9%) | 8 (2%) | 0 |
| Swelling | 102 (29%) | 32 (9%) | 2 (<1%) | 15 (4%) | 1 (<1%) | 0 |
| Vesiculation/ Pustulation | 25 (7%) | 2 (<1%) | 2 (<1%) | 3 (<1%) | 0 | 0 |
| Erosion/ Ulceration | 32 (9%) | 9 (3%) | 0 | 10 (3%) | 0 | 0 |
Table 2 presents the adverse reactions experienced in ≥2% of subjects participating in the controlled clinical trials with KLISYRI. No subject withdrew from the trials due to adverse reactions.
Table 2 : Adverse Reactions Occurring in ≥2% of Subjects in 2 Controlled Clinical Trials– Pooled Safety Population
| Adverse Reaction System Organ Class | KLISYRI N = 353 |
Vehicle N = 349 |
| Number of Subjects (%) with any adverse reaction (possibly related to treatment) | 56 (16%) | 35 (10%) |
| Application site pruritus | 32 (9%) | 21 (6%) |
| Application site paina | 35 (10%) | 11 (3%) |
| a Application site pain includes pain, tenderness, stinging, and burning sensation at the application site. | ||
For the 51 subjects (45 KLISYRI, 6 vehicle) who maintained complete clearance through the 12-month follow-up period, no additional local adverse reactions were reported.
In a multicenter, open-label safety trial of 105 subjects where KLISYRI was applied to a treatment field of 100 cm² on the face or balding scalp, the results were comparable to the safety profile established by the controlled trials in subjects with a 25 cm² treatment area.
Clinical studies in healthy subjects demonstrated KLISYRI did not cause contact sensitization (261 subjects), phototoxic skin reactions (31 subjects), or photoallergic skin reactions (64 subjects).
No Information provided
Included as part of the PRECAUTIONS section.
KLISYRI may cause eye irritation.
Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.
Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation and erosion/ulceration) in the treated area can occur after topical application of KLISYRI [see ADVERSE REACTIONS]. Occlusion after topical application of KLISYRI is more likely to result in irritation. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment.
Advise the patient to read the FDA-approved patient labeling (PATIENT INFORMATION and Instructions for Use).
Advise patients that KLISYRI is not for ophthalmic use. Advise patients to avoid application around the eyes, and transfer of the drug into the eyes and to the periocular area. If accidental exposure occurs, advise patients to flush eyes with water and seek medical care [see WARNINGS AND PRECAUTIONS].
Inform patients that treatment with KLISYRI may lead to local skin reactions [see WARNINGS AND PRECAUTIONS].
Advise patients that KLISYRI is for topical use only. Advise patients to avoid application near and around the eyes, mouth and lips.
Instruct patients to:
No studies have been performed to evaluate the potential of tirbanibulin to induce carcinogenesis.
Tirbanibulin was negative in an in vitro bacterial reverse mutation (Ames) assay. Tirbanibulin was positive in an in vitro chromosomal aberration assay with Chinese hamster ovary (CHO) cells, an in vitro mouse lymphoma assay with L5178/TK+/- cells, and an in vivo micronucleus assay in rats.
Tirbanibulin was assessed for effects on fertility or reproductive function in rats. Reproductive performance of rats was unaffected by oral doses of tirbanibulin up to 4 mg/kg/day (24 times the MRHD on an AUC comparison basis) in males and 1 mg/kg/day (15 times the MRHD on an AUC comparison basis) in females. However, oral administration of 4 mg/kg/day of tirbanibulin to male rats adversely affected spermatogenesis, including reduced sperm count and motility, and increased observations of morphologically abnormal sperm. No effects on sperm were observed in males treated at 2 mg/kg/day (12 times the MRHD on an AUC comparison basis).
There are no available data with KLISYRI use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
In animal reproduction studies, oral administration of tirbanibulin to pregnant rats during the period of organogenesis resulted in an increased incidence of fetal deaths and malformations at a systemic exposure that was at least 19 times the exposure associated with the maximum recommended human dose (MRHD). Oral administration of tirbanibulin to pregnant rabbits during the period of organogenesis resulted in reduced mean fetal weight and size at a systemic exposure that was 41 times the exposure associated with the MRHD (see Data).
The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Animal Data
Tirbanibulin induced fetal deaths and external, visceral, and skeletal malformations when administered orally to pregnant rats during the period of organogenesis at doses greater than or equal to 1.25 mg/kg/day, which resulted in systemic exposures at least 19 times the exposure associated with the MRHD on an Area Under the Curve (AUC) comparison basis. Tirbanibulin had no apparent effects on fetal development in rats at a dose of 0.5 mg/kg/day, which resulted in systemic exposures 5 times the exposure associated with the MRHD.
Tirbanibulin reduced mean fetal weight and size (crown-rump length) when administered orally to pregnant rabbits during the period of organogenesis at a dose of 3 mg/kg/day, which resulted in a systemic exposure 41 times the exposure associated with the MRHD on an AUC comparison basis. Tirbanibulin had no apparent effects on fetal development in rabbits at a dose of 1 mg/kg/day, which resulted in systemic exposures 14 times the exposure associated with the MRHD.
Tirbanibulin was assessed for effects on peri- and post-natal development of rats in a study that involved oral administration to pregnant rats during the period of organogenesis through lactation at dosages up to 1.25 mg/kg/day. These dosages resulted in systemic exposures up to 19 times the exposure associated with the MRHD on an AUC comparison basis. No adverse effects on maternal function or developmental, neurobehavioral, or reproductive performance of offspring were observed.
There are no data on lactational transfer of KLISYRI to human or animal milk. The effects of KLISYRI on the breastfed infant, or its effects on milk production, are unknown.
The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for KLISYRI and any potential adverse effects on the breastfed child from tirbanibulin or from the underlying maternal condition.
The safety and effectiveness of KLISYRI for actinic keratosis in subjects less than 18 years of age have not been established. Actinic keratosis is not a condition generally seen within the pediatric population.
Of the 353 subjects with AK treated with KLISYRI in the 2 controlled Phase 3 trials, 246 (70%) were 65 years of age or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
No Information provided
None.
Tirbanibulin is a microtubule inhibitor. The mechanism of action of KLISYRI for the topical treatment of actinic keratosis is unknown.
The pharmacodynamics of tirbanibulin in the treatment of actinic keratosis is unknown.
Following topical treatment of a mean daily dose of 348 mg (range: 224 to 435 mg) of KLISYRI to a 100 cm² contiguous area of the face or balding scalp, once daily for 5 consecutive days. On Day 5, systemic exposure to tirbanibulin had a mean±SD maximum plasma concentration (Cmax) of 1.32±0.74 ng/mL and 0.71±0.31 ng/mL, and a mean±SD area under the plasma concentration from time zero to 24 hours (AUC24) of 19.6±8.1 h*ng/mL and 11.7±4.4 h*ng/mL, in subjects who received the face and scalp topical treatment, respectively. The median time to reach Cmax (Tmax) was ~6 hours.
Plasma protein binding of tirbanibulin is 88% and is independent of concentrations in the range of 0.01 to 10 μg/mL.
Metabolism
Following topical treatment with KLISYRI to adult subjects with actinic keratosis, the plasma concentrations of KX2-5036, KX2-5163, and KX2-5180, three pharmacologically inactive metabolites, were detectable with the highest plasma concentrations of 0.36 ng/mL, 0.42 ng/mL, and 1.70 ng/mL, respectively.
The in vitro study indicated that incubation of 1 or 10 μM tirbanibulin with human hepatocytes generated KX2-5036, KX2-5162 and other unidentified metabolites.
In vitro, tirbanibulin is mainly metabolized by CYP3A4, and to a lesser extent, CYP2C8.
Excretion
Excretion of tirbanibulin has not been fully characterized in humans.
No clinical studies evaluating the drug interaction potential of KLISYRI have been conducted.
CYP Enzymes
Tirbanibulin and the metabolite KX2-5036 directly or time-dependently inhibited CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4 with an IC50 value of >17 μM. Tirbanibulin up to 1 μM (431.5 ng/mL) and the metabolite KX2-5036 up to 3 μM (1024 ng/mL) did not induce CYP 1A2, 2B6, or 3A4. The metabolite KX2-5180 was neither an inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 or 3A4 with an IC50 value of > 225 nM (85 ng/mL) nor an inducer of CYP1A2, 2B6, and 3A4 at a concentration of 225 nM (85 ng/mL). These findings suggest that KLISYRI has no clinically meaningful effect on the PK of drugs metabolized by CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4.
Drug Transporters
Neither tirbanibulin nor the metabolite KX2-5036 was a substrate of MDR1, BCRP, BSEP, MRP2, MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1 or OCT2. The metabolite KX2-5180 was a substrate of BCRP, but not a substrate for other transporters. Tirbanibulin and the metabolites of KX2-5036 and KX2-5180 inhibited MDR1, BCRP, MRP2, BSEP, MATE1, MATE2-K, OAT1, OTA3, OATP1B1, OATP1B3, OCT1 and/or OCT2 with an IC50 value of >1 μM. The results suggest that KLISYRI has no clinically meaningful effect on the PK of drugs mediated by MDR1, BCRP, MRP2, BSEP, MATE1, MATE2-K, OAT1, OTA3, OATP1B1, OATP1B3, OCT1 and OCT2.
Two double-blind, vehicle-controlled clinical trials (NCT03285477 and NCT03285490) were conducted with 702 adult subjects with actinic keratosis on the face or scalp. Subjects were randomized 1:1 to KLISYRI or vehicle. Subjects enrolled had 4 to 8 clinically typical, visible, and discrete AK lesions in a contiguous area of 25 cm² on the face or scalp. Subjects had an average age of 70 years (range 45 to 96 years), were predominantly White (99%), male (87%), with Fitzpatrick skin types I or II (72%) and actinic keratosis on the face (68%) or scalp (32%). Treatment groups were comparable across all demographics and baseline characteristics, including AK lesion count and distribution on the face or scalp.
Subjects received 5 consecutive days of once daily treatment with either KLISYRI (353) or vehicle control (349) to the treatment field. Subjects with complete (100%) clearance of AK lesions in the treatment area at Day 57 returned to the clinic for recurrence assessment every 3 months for a total of 12 months post-Day 57.
The primary efficacy endpoint was complete (100%) clearance of AK lesions in the treatment area, defined as the proportion of subjects at Day 57 with no clinically visible AK lesions in the treatment area and the secondary endpoint was partial (≥75%) clearance of AK lesions in the treatment area. Results from both trials are presented below.
Table 3 : Complete (100%) AK Clearance Rates on Day 57 in Adults with AK on the Face or Scalp for the Two Phase 3 Trials (Intent to Treat [ITT] Population)
| Study 1 | Study 2 | |||||||
| KLISYRI N = 175 n/N (%) |
Vehicle N = 176 n/N (%) |
Treatment difference (KLISYRI -Vehicle) | 95% Confidence Interval for the Treatment difference | KLISYRI N = 178 n/N (%) |
Vehicle N = 173 n/N (%) |
Treatment difference (KLISYRI -Vehicle) | 95% Confidence Interval for the Treatment difference | |
| All subjects | 77/175 (44%) | 8/176 (5%) | 40%a | (31.6%, 47.5%)a | 97/178 (54%) | 22/173 (13%) |
42% a | (33.1%, 50.7%)a |
| Face | 60/119 (50%) | 7/121 (6%) | 45% | -- | 73/119 (61%) | 16/118 (14%) | 48% | -- |
| Scalp | 17/56 (30%) | 1/55 (2%) | 29% | -- | 24/59 (41%) | 6/55 (11%) | 30% | -- |
| a Based on Mantel-Haenszel method | ||||||||
Table 4 : Partial (≥ 75%) AK Clearance Rates on Day 57 in Adults with AK on the Face or Scalp for the Two Phase 3 Trials (Intent to Treat [ITT] Population)
| Study 1 | Study 2 | |||||||
| KLISYRI N = 175 n/N (%) |
Vehicle N = 176 n/N (%) |
Treatment difference (KLISYRI -Vehicle) | 95% Confidence Interval for the Treatment difference | KLISYRI N = 178 n/N (%) |
Vehicle N = 173 n/N (%) |
Treatment difference (KLISYRI -Vehicle) | 95% Confidence Interval for the Treatment difference | |
| All subjects | 119/175 (68%) | 29/176 (16%) | 52% a | (42.9%, 60.3%) a | 136/178 (76%) | 34/173 (20%) | 57% a | (48.3%, 65.4%) a |
| Face | 90/119 (76%) | 23/121 (19%) | 57% | -- | 95/119 (80%) | 26/118 (22%) | 58% | -- |
| Scalp | 29/56 (52%) | 6/55 (11%) | 41% | -- | 41/59 (69%) | 8/55 (15%) | 55% | -- |
| a Based on Mantel-Haenszel method | ||||||||
Efficacy was consistent across sex and age (<65 and ≥65 years) subgroups.
Subjects who achieved 100% clearance of AK lesions in the treatment area at Day 57 continued to be followed for up to 12 months following Day 57 to determine the recurrence rate. Recurrence was defined as the proportion of subjects with any identified AK lesion (new or previous lesion) in the previously treated area who achieved 100% clearance at Day 57. Of the 174 subjects treated with KLISYRI who were followed, the recurrence rate at 12 months post-Day 57 was 73%.
KLISYRI
(klye si' ree)
(tirbanibulin) ointment
Important: KLISYRI is for use on the skin only (topical). Do not use KLISYRI in, around, or near your eyes, mouth or lips.
What is KLISYRI?
KLISYRI is a prescription medicine used on the skin to treat actinic keratosis on the face or scalp.
It is not known if KLISYRI is safe and effective in children less than 18 years of age.
Before using KLISYRI, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
How should I use KLISYRI?
What are the possible side effects of KLISYRI?
KLISYRI may cause serious side effects, including:
The most common side effects of KLISYRI include: itching or pain in the treatment area.
These are not all of the possible side effects of KLISYRI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store KLISYRI?
General Information about the safe and effective use of KLISYRI.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use KLISYRI for a condition for which it was not prescribed. Do not give KLISYRI to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about
KLISYRI that is written for health professionals.
What are the ingredients of KLISYRI?
Active ingredient: Tirbanibulin
Inactive ingredients: Mono- and di-glycerides and propylene glycol.
This Patient Information has been approved by the U.S. Food and Drug Administration.
